@article{oai:u-ryukyu.repo.nii.ac.jp:02012395,
 author = {Kusada, Takeaki and Toita, Takafumi and Ariga, Takuro and Maemoto, Hitoshi and Hashimoto, Seiji and Shiina, Hideki and Kakinohana, Yasumasa and Joichi, Heianna and Nagai, Yutaka and Kudaka, Wataru and Aoki, Youichi and Murayama, Sadayuki},
 issue = {1},
 journal = {Journal of Radiation Research},
 month = {Jan},
 note = {This study evaluated the oncologic outcomes and complications of cervical cancer patients in terms of CT-based image-guided brachytherapy (IGBT) parameters. Of 68 cervical cancer patients treated with definitive radiotherapy/concurrent chemoradiotherapy, most received whole-pelvis external beam RT (EBRT) of 40 Gy in 20 fractions, pelvic EBRT with central shield of 10 Gy in 5 fractions, and CT-based IGBT of 18 Gy in 3 fractions prescribed to point A. Cumulative EBRT and IGBT doses were calculated as the total equivalent dose in 2 Gy fractions (EQD2). The median follow-up was 31 (3–52) months. The 2-year overall survival, local control, pelvic control, and disease-free survival rates of the 68 patients were 92%, 83%, 82% and 73%, respectively. The HR-CTV D90, length from the tandem axis to left/right margin of the HR-CTV (T-LR), and HR-CTV volume were significant IGBT parameters for predicting local/pelvic control. Patients who received an HR-CTV D90 of >60 Gy, compared with ≤60 Gy, had significantly better local/pelvic control. Furthermore, 70 Gy was a marginally significant HR-CTV D90 cut-off affecting local control. T-LR was an independent IGBT parameter predicting local/pelvic control on multivariate analysis. Three patients developed Grade 3 or higher treatment-related complications. The D2cm3 of organs at risk were not significant predictors of complications. Future challenges for further improving outcomes include additional interstitial needles for irregularly shaped HR-CTVs, and moderate dose escalation, especially for patients with poor tumor responses., 論文},
 pages = {67--76},
 title = {Computed tomography–based image-guided brachytherapy for cervical cancer : correlations between dose–volume parameters and clinical outcomes},
 volume = {59},
 year = {2018}
}